Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Oct;70(10):7030–7038. doi: 10.1128/jvi.70.10.7030-7038.1996

Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.

H Zhou 1, W O'Neal 1, N Morral 1, A L Beaudet 1
PMCID: PMC190753  PMID: 8794347

Abstract

Although adenovirus vectors offer many advantages, it would be desirable to develop vectors with improved expression and decreased toxicity. Toward this objective, an adenovirus vector system with deletion of both the El and E2a regions was developed. A 5.9-kb fragment of the adenovirus type 5 (Ad5) genome containing the E2a gene and its early and late promoters was transfected into 293 cells. A complementing cell line, designated 293-C2, expressed the E2a mRNA and protein and was found to complement the defect in Ad5 viruses with temperature-sensitive or deletion mutations in E2a. A deletion of 1.3 kb removing codons 40 to 471 of the 529 amino acids of E2a was introduced into plasmids for preparation of viruses and vectors. An Ad5 virus with disruption of the El gene and deletion of E2a grew on 293-C2 cells but not on 293 cells. Vectors with E1 and E2a deleted expressing Escherichia coli beta-galactosidase or human alpha1-antitrypsin were prepared and expressed the reporter genes after intravenous injection into mice. This vector system retains sequences in common between the complementing cell line and the vectors, including 3.4 kb upstream and 1.1 kb downstream of the deletion. These vectors have potential advantages of increased capacity for insertion of transgene sequences, elimination of expression of E2a, and possibly reduction in expression of other viral proteins. Although the titers of the vectors with deleted are about 10- to 30-fold below those of vectors with E2a wild-type regions, the former vectors are suitable for detailed studies with animals to evaluate the effects on host immune responses, on duration of expression, and on safety.

Full Text

The Full Text of this article is available as a PDF (622.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amalfitano A., Begy C. R., Chamberlain J. S. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3352–3356. doi: 10.1073/pnas.93.8.3352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Armentano D., Sookdeo C. C., Hehir K. M., Gregory R. J., St George J. A., Prince G. A., Wadsworth S. C., Smith A. E. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther. 1995 Oct;6(10):1343–1353. doi: 10.1089/hum.1995.6.10-1343. [DOI] [PubMed] [Google Scholar]
  3. Barr D., Tubb J., Ferguson D., Scaria A., Lieber A., Wilson C., Perkins J., Kay M. A. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 1995 Mar;2(2):151–155. [PubMed] [Google Scholar]
  4. Berkner K. L. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques. 1988 Jul-Aug;6(7):616–629. [PubMed] [Google Scholar]
  5. Bett A. J., Haddara W., Prevec L., Graham F. L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8802–8806. doi: 10.1073/pnas.91.19.8802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Boucher R. C. Current status of CF gene therapy. Trends Genet. 1996 Mar;12(3):81–84. doi: 10.1016/0168-9525(96)81410-7. [DOI] [PubMed] [Google Scholar]
  7. Bramson J. L., Graham F. L., Gauldie J. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Biotechnol. 1995 Oct;6(5):590–595. doi: 10.1016/0958-1669(95)80097-2. [DOI] [PubMed] [Google Scholar]
  8. Brody S. L., Metzger M., Danel C., Rosenfeld M. A., Crystal R. G. Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther. 1994 Jul;5(7):821–836. doi: 10.1089/hum.1994.5.7-821. [DOI] [PubMed] [Google Scholar]
  9. Brough D. E., Cleghon V., Klessig D. F. Construction, characterization, and utilization of cell lines which inducibly express the adenovirus DNA-binding protein. Virology. 1992 Oct;190(2):624–634. doi: 10.1016/0042-6822(92)90900-a. [DOI] [PubMed] [Google Scholar]
  10. COUCH R. B., CHANOCK R. M., CATE T. R., LANG D. J., KNIGHT V., HUEBNER R. J. IMMUNIZATION WITH TYPES 4 AND 7 ADENOVIRUS BY SELECTIVE INFECTION OF THE INTESTINAL TRACT. Am Rev Respir Dis. 1963 Sep;88:SUPPL–403. doi: 10.1164/arrd.1963.88.3P2.394. [DOI] [PubMed] [Google Scholar]
  11. Chang L. S., Shenk T. The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters. J Virol. 1990 May;64(5):2103–2109. doi: 10.1128/jvi.64.5.2103-2109.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Crystal R. G., McElvaney N. G., Rosenfeld M. A., Chu C. S., Mastrangeli A., Hay J. G., Brody S. L., Jaffe H. A., Eissa N. T., Danel C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet. 1994 Sep;8(1):42–51. doi: 10.1038/ng0994-42. [DOI] [PubMed] [Google Scholar]
  13. Crystal R. G. Transfer of genes to humans: early lessons and obstacles to success. Science. 1995 Oct 20;270(5235):404–410. doi: 10.1126/science.270.5235.404. [DOI] [PubMed] [Google Scholar]
  14. Engelhardt J. F., Ye X., Doranz B., Wilson J. M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6196–6200. doi: 10.1073/pnas.91.13.6196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ensinger M. J., Ginsberg H. S. Selection and preliminary characterization of temperature-sensitive mutants of type 5 adenovirus. J Virol. 1972 Sep;10(3):328–339. doi: 10.1128/jvi.10.3.328-339.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fang B., Wang H., Gordon G., Bellinger D. A., Read M. S., Brinkhous K. M., Woo S. L., Eisensmith R. C. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther. 1996 Mar;3(3):217–222. [PubMed] [Google Scholar]
  17. Fisher K. J., Choi H., Burda J., Chen S. J., Wilson J. M. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology. 1996 Mar 1;217(1):11–22. doi: 10.1006/viro.1996.0088. [DOI] [PubMed] [Google Scholar]
  18. French B. A., Mazur W., Ali N. M., Geske R. S., Finnigan J. P., Rodgers G. P., Roberts R., Raizner A. E. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation. 1994 Nov;90(5):2402–2413. doi: 10.1161/01.cir.90.5.2402. [DOI] [PubMed] [Google Scholar]
  19. Ginsberg H. S., Williams J. F., Doerfler W. H., Shimojo H. Proposed nomenclature for mutants of adenoviruses. J Virol. 1973 Sep;12(3):663–664. doi: 10.1128/jvi.12.3.663-664.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Goldman M. J., Litzky L. A., Engelhardt J. F., Wilson J. M. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. Hum Gene Ther. 1995 Jul;6(7):839–851. doi: 10.1089/hum.1995.6.7-839. [DOI] [PubMed] [Google Scholar]
  21. Gorziglia M. I., Kadan M. J., Yei S., Lim J., Lee G. M., Luthra R., Trapnell B. C. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol. 1996 Jun;70(6):4173–4178. doi: 10.1128/jvi.70.6.4173-4178.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Graham F. L. Covalently closed circles of human adenovirus DNA are infectious. EMBO J. 1984 Dec 1;3(12):2917–2922. doi: 10.1002/j.1460-2075.1984.tb02232.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Graham F. L., Rudy J., Brinkley P. Infectious circular DNA of human adenovirus type 5: regeneration of viral DNA termini from molecules lacking terminal sequences. EMBO J. 1989 Jul;8(7):2077–2085. doi: 10.1002/j.1460-2075.1989.tb03616.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Graham F. L., Smiley J., Russell W. C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977 Jul;36(1):59–74. doi: 10.1099/0022-1317-36-1-59. [DOI] [PubMed] [Google Scholar]
  25. Herrmann F. Cancer gene therapy: principles, problems, and perspectives. J Mol Med (Berl) 1995 Apr;73(4):157–163. doi: 10.1007/BF00188136. [DOI] [PubMed] [Google Scholar]
  26. Kay M. A., Graham F., Leland F., Woo S. L. Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology. 1995 Mar;21(3):815–819. [PubMed] [Google Scholar]
  27. Klessig D. F., Brough D. E., Cleghon V. Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell. Mol Cell Biol. 1984 Jul;4(7):1354–1362. doi: 10.1128/mcb.4.7.1354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kochanek S., Clemens P. R., Mitani K., Chen H. H., Chan S., Caskey C. T. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5731–5736. doi: 10.1073/pnas.93.12.5731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Krougliak V., Graham F. L. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther. 1995 Dec;6(12):1575–1586. doi: 10.1089/hum.1995.6.12-1575. [DOI] [PubMed] [Google Scholar]
  30. McGrory W. J., Bautista D. S., Graham F. L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology. 1988 Apr;163(2):614–617. doi: 10.1016/0042-6822(88)90302-9. [DOI] [PubMed] [Google Scholar]
  31. Mittereder N., Yei S., Bachurski C., Cuppoletti J., Whitsett J. A., Tolstoshev P., Trapnell B. C. Evaluation of the efficacy and safety of in vitro, adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther. 1994 Jun;5(6):717–729. doi: 10.1089/hum.1994.5.6-717. [DOI] [PubMed] [Google Scholar]
  32. Mizushima S., Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 1990 Sep 11;18(17):5322–5322. doi: 10.1093/nar/18.17.5322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Morgan J. E. Cell and gene therapy in Duchenne muscular dystrophy. Hum Gene Ther. 1994 Feb;5(2):165–173. doi: 10.1089/hum.1994.5.2-165. [DOI] [PubMed] [Google Scholar]
  34. Morsy M. A., Alford E. L., Bett A., Graham F. L., Caskey C. T. Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes. J Clin Invest. 1993 Sep;92(3):1580–1586. doi: 10.1172/JCI116739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Neve R. L. Adenovirus vectors enter the brain. Trends Neurosci. 1993 Jul;16(7):251–253. doi: 10.1016/0166-2236(93)90174-k. [DOI] [PubMed] [Google Scholar]
  36. Nicolas J. C., Sarnow P., Girard M., Levine A. J. Host range temperature-conditional mutants in the adenovirus DNA binding protein are defective in the assembly of infectious virus. Virology. 1983 Apr 15;126(1):228–239. doi: 10.1016/0042-6822(83)90474-9. [DOI] [PubMed] [Google Scholar]
  37. O'Connor R. J., Hearing P. Mutually exclusive interaction of the adenovirus E4-6/7 protein and the retinoblastoma gene product with internal domains of E2F-1 and DP-1. J Virol. 1994 Nov;68(11):6848–6862. doi: 10.1128/jvi.68.11.6848-6862.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. O'Neal W. K., Beaudet A. L. Somatic gene therapy for cystic fibrosis. Hum Mol Genet. 1994;3(Spec No):1497–1502. doi: 10.1093/hmg/3.suppl_1.1497. [DOI] [PubMed] [Google Scholar]
  39. Rice S. A., Klessig D. F. Isolation and analysis of adenovirus type 5 mutants containing deletions in the gene encoding the DNA-binding protein. J Virol. 1985 Dec;56(3):767–778. doi: 10.1128/jvi.56.3.767-778.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991 Feb 22;64(4):693–702. doi: 10.1016/0092-8674(91)90499-o. [DOI] [PubMed] [Google Scholar]
  41. Stratford-Perricaudet L. D., Makeh I., Perricaudet M., Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest. 1992 Aug;90(2):626–630. doi: 10.1172/JCI115902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Top F. H., Jr, Buescher E. L., Bancroft W. H., Russell P. K. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis. 1971 Aug;124(2):155–160. doi: 10.1093/infdis/124.2.155. [DOI] [PubMed] [Google Scholar]
  43. Tsuji M., van der Vliet P. C., Kitchingman G. R. Temperature-sensitive mutants of adenovirus single-stranded DNA-binding protein. Inability to support DNA replication is associated with an altered DNA-binding activity of the protein. J Biol Chem. 1991 Aug 25;266(24):16178–16187. [PubMed] [Google Scholar]
  44. Van Der Vliet P. C., Levine A. J., Ensinger M. J., Ginsberg H. S. Thermolabile DNA binding proteins from cells infected with a temperature-sensitive mutant of adenovrius defective in viral DNA synthesis. J Virol. 1975 Feb;15(2):348–354. doi: 10.1128/jvi.15.2.348-354.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Voelkerding K., Klessig D. F. Identification of two nuclear subclasses of the adenovirus type 5-encoded DNA-binding protein. J Virol. 1986 Nov;60(2):353–362. doi: 10.1128/jvi.60.2.353-362.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Wang Q., Jia X. C., Finer M. H. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther. 1995 Dec;2(10):775–783. [PubMed] [Google Scholar]
  47. Yang Y., Nunes F. A., Berencsi K., Furth E. E., Gönczöl E., Wilson J. M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4407–4411. doi: 10.1073/pnas.91.10.4407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Yang Y., Nunes F. A., Berencsi K., Gönczöl E., Engelhardt J. F., Wilson J. M. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet. 1994 Jul;7(3):362–369. doi: 10.1038/ng0794-362. [DOI] [PubMed] [Google Scholar]
  49. Yei S., Mittereder N., Wert S., Whitsett J. A., Wilmott R. W., Trapnell B. C. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther. 1994 Jun;5(6):731–744. doi: 10.1089/hum.1994.5.6-731. [DOI] [PubMed] [Google Scholar]
  50. Zsengeller Z. K., Wert S. E., Hull W. M., Hu X., Yei S., Trapnell B. C., Whitsett J. A. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther. 1995 Apr;6(4):457–467. doi: 10.1089/hum.1995.6.4-457. [DOI] [PubMed] [Google Scholar]
  51. van Ormondt H., Galibert F. Nucleotide sequences of adenovirus DNAs. Curr Top Microbiol Immunol. 1984;110:73–142. doi: 10.1007/978-3-642-46494-2_4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES